(S16) Strengthening Cardiometabolic-Kidney Care: Real-World Application of Guidelines for DCES Practice

Saturday, August 8, 2026

1:00 PM - 1:45 PM ET

CE: .75 CE

Pharmacology Hours: .50 CE

Elevate your impact as a DCES by learning how to translate the latest ADA Standards into real-world strategies for cardiometabolic-kidney (CKM) care. This session highlights key guideline updates, evidence-based interventions, and practical approaches to optimizing outcomes for people with T2D, kidney disease, cardiovascular risk, and metabolic challenges. Attendees will gain actionable tools to integrate pharmacologic therapy, lifestyle interventions, and technology into individualized care plans, while enhancing person-centered education and interdisciplinary collaboration. Walk away with concrete strategies to transform guidelines into measurable improvements in CKM health.

Learning Objectives:

At the completion of this activity, participants should be able to:

Describe key updates in the 2026 ADA Standards that impact cardiometabolic-kidney (CKM) care and outcomes for people with diabetes.
Apply evidence-based guideline recommendations to optimize pharmacologic, lifestyle, and technology-based interventions for people with CKM risk factors.
Identify strategies for translating CKM-focused guideline updates into practical diabetes self-management education, care planning, and team-based interventions.

Disclosure(s):

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP: Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP: Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Dexcom: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Mannkind: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Tandem: Consultant / Advisory Board (Ongoing)

Primary Presenter(s)

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP (she/her/hers)

Professor, Pharmacy Practice, PGY2 Ambulatory Care Residency Program Director, Clinical Pharmacist
Midwestern University College of Pharmacy and Northwestern Medicine

Disclosure(s): Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)

Co-Presenter(s)

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP (she/her/hers)

Endocrine Clinical Pharmacy Specialist
Cleveland Clinic Endocrinology & Metabolism Institute

Disclosure(s): Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Dexcom: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Mannkind: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Tandem: Consultant / Advisory Board (Ongoing)